Podcasts about carfilzomib

Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett speaks to Proactive about the potential clinical utility of its lead asset, bisantrene. The biotech this week reached a new 12-month high following strong preclinical findings on the efficacy of bisantrene in treating multiple myeloma. Shares increased by 7.95% to A$2.04, with the company's market capitalisation around A$339.25 million. Multiple myeloma, a dangerous blood cancer more common in men over 60, accounts for 10% of blood cancers with a five-year survival rate of 55.6%. Carfilzomib, a drug used for relapsed or refractory multiple myeloma, carries known cardiotoxicity risks, particularly in patients with pre-existing heart conditions. Preclinical studies performed by Labcorp USA indicated that bisantrene, both alone and in combination with carfilzomib, slows disease progression and enhances carfilzomib's efficacy. Bisantrene killed human multiple myeloma cells at clinically relevant concentrations in both cell cultures and mice, and in combination with carfilzomib, showed enhanced activity, suggesting a potentially safer treatment. In 2021, Race discovered that bisantrene could protect human heart muscle cells from carfilzomib's toxicity. Mouse model studies showed that bisantrene significantly slowed multiple myeloma progression, while carfilzomib alone, at its maximum tolerated dosage, showed no single-agent activity. The combination of bisantrene and carfilzomib proved more effective than bisantrene alone, indicating a synergistic effect. Race plans further preclinical studies to investigate the cellular mechanisms of the delayed progression of multiple myeloma and to confirm bisantrene's cardioprotective properties. The company also intends to explore clinical studies to evaluate the combination treatment for multiple myeloma patients. #ProactiveInvestors #RaceOncology #ASX #RAC #MultipleMyeloma, #Bisantrene, #Carfilzomib, #CancerResearch, #PreclinicalStudies, #BloodCancer, #CancerTreatment #Oncology #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

When you're dealing with a disease like cancer, any treatment that keeps it at bay is a big help. But what happens when coverage for that treatment runs out? Gregory Lush has been battling cancer since 2018, and was put on a chemo drug called Carfilzomib in January 2022. Last week, Lush and his family were informed that the coverage for the drug has ended. We spoke with Gregory Lush's daughter-in-law, Crystal Casey.

CME credits: 1.00 Valid until: 25-08-2024 Claim your CME credit at https://reachmd.com/programs/cme/carfilzomib-based-regimens-for-early-relapse-multiple-myeloma/16012/ Recognizing and treating early relapse of multiple myeloma (MM) is a challenge for healthcare professionals. This program is designed to improve clinicians' ability to distinguish between relapse and progression of disease in MM. In addition, the program compares the efficacy and safety of carfilzomib- and pomalidomide-based regimens in the treatment of relapsed MM, applies current and emerging treatment approaches to MM patients in early relapse, and reviews common adverse events that occur when using combination regimens to treat early relapsed myeloma.

Joseph Mikhael, MD, and Saad Usmani, MD, discuss options in managing triple-class refractory multiple myeloma including selinexor, belantamab mafodotin, and CAR T-cell therapy. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/964339). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Myeloma https://emedicine.medscape.com/article/204369-overview Selinexor Prescribing Information https://www.karyopharm.com/wp-content/uploads/2019/07/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf Belantamab Mafodotin Prescribing Information https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Blenrep/pdf/BLENREP-PI-MG.PDF Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview Trending Clinical Topic: CAR T-cell Therapy https://reference.medscape.com/viewarticle/965011 Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor https://www.karyopharm.com/wp-content/uploads/2020/06/Consensus-Recommendations_June2020.pdf Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932935/ Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Carfilzomib Nonrefractory Multiple Myeloma (MM) Patients. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8038 Ide-cel Prescribing Information https://packageinserts.bms.com/pi/pi_abecma.pdf Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-label, Phase 2 Study https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(19)30788-0 DREAMM Trials https://dreammtrials.com/ Blenrep (Belantamab Mafodotin) REMS https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=403 Band Keratopathy https://emedicine.medscape.com/article/1194813-overview Cilta-cel Prescribing Information https://www.fda.gov/media/156560/download BCMA-Directed CAR T-cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT04318327

Joseph Mikhael, MD, and Ashley Rosko, MD, discuss the role of comorbidities in multiple myeloma and stress the importance of shifting away from the sole use of age-based treatment decisions. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/964338). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Myeloma https://emedicine.medscape.com/article/204369-overview International Myeloma Working Group Frailty Score Calculator http://www.myelomafrailtyscorecalculator.net/ R-MCI: Myeloma Comorbidity Index https://www.myelomacomorbidityindex.org/en_calc.html A Simplified Frailty Scale Predicts Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated in the FIRST (MM-020) Trial https://www.nature.com/articles/s41375-019-0539-0 Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline https://ascopubs.org/doi/full/10.1200/JCO.18.02096 Frailty in Older Adults: Evidence for a Phenotype https://academic.oup.com/biomedgerontology/article/56/3/M146/545770 Comprehensive Geriatric Assessment https://www.uptodate.com/contents/comprehensive-geriatric-assessment Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma Without Intention for Immediate Autologous Stem-Cell Transplantation (ENDURANCE): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591827/

Joseph Mikhael, MD, and Peter Voorhees, MD, discuss frontline therapy for multiple myeloma and new options for both transplant-eligible and transplant-ineligible patients. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/964337). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources International Myeloma Foundation https://www.myeloma.org/ Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278911/pdf/i0018-5787-52-1-27.pdf Carfilzomib, Lenalidomide, and Dexamethasone Plus Transplant in Newly Diagnosed Multiple Myeloma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714092/ Maintenance With Daratumumab or Observation Following Treatment With Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab and Autologous Stem-Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma (CASSIOPEIA): An Open-Label, Randomised, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00428-9/fulltext Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial https://ashpublications.org/blood/article/136/8/936/454474/Daratumumab-lenalidomide-bortezomib-and Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 24 Months of Maintenance https://ash.confex.com/ash/2021/webprogram/Paper149024.html Venetoclax or Placebo in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (BELLINI): A Randomised, Double-Blind, Multicentre, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30525-8/fulltext Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial https://ash.confex.com/ash/2021/webprogram/Paper145097.html Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma https://ascopubs.org/doi/10.1200/JCO.21.01935 Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma Without Intention for Immediate Autologous Stem-Cell Transplantation (ENDURANCE): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial https://www.thelancet.com/article/S1470-2045(20)30452-6/fulltext Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma The MANHATTAN Nonrandomized Clinical Trial https://jamanetwork.com/journals/jamaoncology/fullarticle/2778195 Carfilzomib or Bortezomib in Relapsed or Refractory Multiple Myeloma (ENDEAVOR): An Interim Overall Survival Analysis of an Open-Label, Randomised, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30578-8/fulltext Carfilzomib With Cyclophosphamide and Dexamethasone or Lenalidomide and Dexamethasone Plus Autologous Transplantation or Carfilzomib Plus Lenalidomide and Dexamethasone, Followed by Maintenance With Carfilzomib Plus Lenalidomide or Lenalidomide Alone for Patients With Newly Diagnosed Multiple Myeloma (FORTE): A Randomised, Open-Label, Phase 2 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00535-0/fulltext Lenalidomide, Bortezomib, and Dexamethasone With Transplantation for Myeloma https://www.nejm.org/doi/full/10.1056/NEJMoa1611750

Foundations of OncoPharm: Carfilzomib (and a fair bit of bortezomib)

Listen to a soundcast of the November 29, 2021 and November 30, 2021 FDA approvals of Cytalux (pafolacianine) for identifying malignant ovarian cancer lesions and Darzalex Faspro (daratumumab + hyaluronidase-fihj), Kyprolis (carfilzomib) and dexamethasone for multiple myeloma.

Host: Jennifer Caudle, DO Guest: Joseph Mikhael, MD Many patients with multiple myeloma receive an immunomodulatory agent (IMiD) as part of their initial treatment, leading to a growing interest in what a patient's next treatment should be if they don't respond or become refractory to IMiDs. With the approval of an IMid-free regimen based on the CANDOR study results, these patients now have a treatment option.2 Drs. Jennifer Caudle and Joseph Mikhael discuss the regimen and the CANDOR study, including the key findings that came out of the study. 1. Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396:186-197.2. KYPROLIS® (carfilzomib) prescribing information, Onyx Pharmaceuticals Inc., an Amgen Inc. subsidiary. USA-171-81544 9/2021

1:08 - Take-home thoughts for R/R MM 3:47 - Summary of BCMA-targeted CAR T-cell therapy; Use of novel agents for R/R MM6:47 - Information on melphalan flufenamide; Combination approaches with selinexor in clinical practice9:59 - Cost considerations for treatment options in R/R MM12:25 - Administration considerations for subcutaneous daratumumab and venetoclax in R/R MMFacultyKathryn Maples, PharmD, BCOPClinical Pharmacy Specialist, Multiple MyelomaWinship Cancer Institute, Emory HealthcareAtlanta, GeorgiaTim Peterson, PharmD, BCOPClinical Pharmacy Specialist – Multiple MyelomaMemorial Sloan Kettering Cancer CenterNew York, New York Content based on a CE activity supported by educational grants from Karyopharm Therapeutics, Inc. and Oncopeptides, Inc.Link to full activity: https://www.proce.com/RRMM

In this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on how to select the optimal therapy for patients with relapse/refractory multiple myeloma. Topics include:Treatment after first relapsedOptimal use of CAR T-cell therapyWhen to use selinexor and belantamab mafodotinCOVID-19 vaccinations for patients with myelomaPresenters:Paul G. Richardson, MDR. J. Corman Professor of MedicineHarvard Medical SchoolClinical Program LeaderDirector of Clinical ResearchJerome Lipper Multiple Myeloma CenterDana-Farber Cancer InstituteBoston, MassachusettsNina Shah, MDProfessor of Clinical MedicineDivision of Hematology-OncologyDepartment of MedicineUniversity of California San FranciscoSan Francisco, CaliforniaPeter M. Voorhees, MDDirector, Medical Operations and Outreach ServicesDepartment of Hematology/OncologyLevine Cancer Institute, Atrium HealthCharlotte, North CarolinaContent based on an online CME program supported by educational grants from Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm, Oncopeptides, and Sanofi Genzyme.Link to full program:https://bit.ly/2UIhXcL

Dr. Moreau discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma, key findings from the pivotal IKEMA trial, and future directions with the combination.

In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses clinical considerations for diagnosis and optimal treatment selection for initial management of patients with multiple myeloma. Topics in this podcast include:IMWG criteria for diagnosing smoldering and active myelomaRisk stratification of smoldering myeloma with 2/20/20 criteria and active myeloma with R-ISS stagingIndividualizing initial treatment for ASCT-ineligible myelomaSelecting optimal initial treatment for ASCT-eligible myelomaPresenter: Beth Faiman, PhD, MSN, APRN-BC, AOCNNurse PractitionerCleveland Clinic Taussig Cancer InstituteCleveland, OhioCE/AAPA credit available by visiting the online program: https://bit.ly/3ee9IvsLink to full program, including downloadable slidesets: https://bit.ly/3ee9Ivs

In this podcast episode,Charise Gleason, MSN, NP-BC, AOCNP, discusses clinical considerations for patients with multiple myeloma after relapse on initial therapy. Topics in this podcast include:Strategies for monitoring for disease progressionDisease, therapy, and patient considerations for treatment selection at first relapseNursing implications and supportive care considerations for patients receiving therapy for relapsed diseasePresenter:Charise Gleason, MSN, NP-BC, AOCNPAdvanced Practice Provider ChiefWinship Cancer InstituteAdjunct FacultyNell Hodgson Woodruff School of NursingEmory UniversityAtlanta, GeorgiaCE/AAPA credit available by visiting the online program: https://bit.ly/3ee9IvsLink to full program, including downloadable slidesets:https://bit.ly/3ee9Ivs

In this podcast episode, Suzanne Lentzsch, MD, PhD, and  Saad Z. Usmani, MD, MBA, FACP, discuss how they select optimal treatment for relapsed/refractory (R/R) multiple myeloma (MM) and answer audience questions from a live webinar. Topics include:Selecting optimal triplet regimen after first relapseSequencing treatment options after multiple relapsesManaging patient expectations when selecting treatmentsEmerging treatment options for R/R MMPresenters:  Suzanne Lentzsch, MD, PhDDirector, Multiple Myeloma and Amyloidosis ProgramProfessor of MedicineDivision of Hematology/OncologyColumbia University Medical CenterNew York, New YorkSaad Z. Usmani, MD, MBA, FACPClinical Professor of MedicineDepartment of Hematologic Oncology & Blood DisordersDivision ChiefPlasma Cell Disorders DivisionLevine Cancer Institute/Atrium HealthCharlotte, North CarolinaSupported by educational grants from Amgen; Bristol-Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Oncopeptides.Link to full program, including an downloadable slidesets and an on-demand webcast:https://bit.ly/3gjr62p

In this episode,  Shaji K. Kumar, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD, and Jesús F. San-Miguel, MD, PhD, answer audience questions from a recent Clinical Care Options live webinar on managing multiple myeloma. Topics include:Approaches for managing smoldering multiple myelomaInsights on new strategies for managing newly diagnosed multiple myelomaIncorporating newly approved agents in the frontline and early relapse settingChoosing and sequencing BCMA-targeted therapiesManaging patients with refractory multiple myelomaPresenters:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematological MalignanciesChair, Myeloma Amyloidosis Dysproteinemia GroupConsultant, Division of HematologyMayo ClinicRochester, MinnesotaThomas G. Martin, MDClinical Professor of MedicineAssociate Director, Myeloma ProgramUniversity of California, San Francisco Medical CenterSan Francisco, CaliforniaPhilippe Moreau, MDProfessor of Clinical HematologyHead, Hematology DepartmentUniversity Hospital Hôtel-DieuNantes, FranceS. Vincent Rajkumar, MDEdward W. and Betty Knight Scripps Professor of MedicineMayo ClinicRochester, MinnesotaJesús F. San-Miguel, MD, PhDDirector of Clinical and Translational MedicineUniversidad de NavarraPamplona, SpainSupported by educational grants from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm and Oncopeptides.Link to full program, including downloadable slidesets and expert commentaries:https://bit.ly/39MWNid 

Listen to a soundcast of the March 31, 2021 FDA approval of Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone for treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.

FDA 批准治疗慢性免疫性血小板减少症的新药BMJ 术后血栓预防中，加压袜并不能提供额外的获益Nature子刊 白血病治疗性疫苗的研制阿凡波帕（avatrombopag）阿凡波帕（avatrombopag）血小板生成素受体激动剂。在上周三《消化科星期三 Episode 23》中已经给介绍了阿凡波帕用于治疗慢性肝病合并血小板减少患者的手术前用药，可以改善血小板计数、减少出血和输血。2019年6月，该药的适应症被扩展至慢性免疫性血小板减少。《随机对照研究：阿凡波帕治疗慢性免疫血小板减少症的3期临床研究》British Journal of Haematology，2018年11月 (1)这个安慰剂对照、多中心、随机、双盲的3阶段的研究，目的是评估阿凡波帕20mg qd治疗成人慢性、免疫性血小板减少症的疗效。研究纳入49位患者，入组时血小板计数

FDA 批准治疗慢性免疫性血小板减少症的新药BMJ 术后血栓预防中，加压袜并不能提供额外的获益Nature子刊 白血病治疗性疫苗的研制阿凡波帕（avatrombopag）阿凡波帕（avatrombopag）血小板生成素受体激动剂。在上周三《消化科星期三 Episode 23》中已经给介绍了阿凡波帕用于治疗慢性肝病合并血小板减少患者的手术前用药，可以改善血小板计数、减少出血和输血。2019年6月，该药的适应症被扩展至慢性免疫性血小板减少。《随机对照研究：阿凡波帕治疗慢性免疫血小板减少症的3期临床研究》British Journal of Haematology，2018年11月 (1)这个安慰剂对照、多中心、随机、双盲的3阶段的研究，目的是评估阿凡波帕20mg qd治疗成人慢性、免疫性血小板减少症的疗效。研究纳入49位患者，入组时血小板计数

In this episode, Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and  Prof. Dr. med. Katja Weisel answer questions focused on current and emerging therapies for early and late relapsed, refractory multiple myeloma, with topics including:• Responses across different subgroups treated with idecabtagene vicleucel in the KarMMa trial • Selecting therapy for a patient with lenalidomide-refractory disease at first relapse• How CAR T-cell therapy, melflufen, and selinexor will fit into existing and future treatment algorithms• Key findings from the DREAMM2 trial on belantamab mafodotin• Monitoring and management strategies for ocular toxicity with belantamab mafodotinPresenters:Jesús F. San-Miguel, MD, PhDDirector of Clinical and Translational MedicineUniversidad de NavarraPamplona, SpainPaula Rodriguez-Otero, MD, PhDAssociate ProfessorConsultant in HematologyDepartment of Hematology, Clínica Universidad de NavarraUniversity of NavarraPamplona, SpainProf. Dr. med. Katja Weisel  Deputy DirectorII. Medical Clinic and PolyclinicDepartment of Oncology and HematologyDepartment of Pneumology and Bone Marrow TransplantationUniversity Medical Center  Hamburg-EppendorfHamburg, GermanyContent based on an online CME program supported by an educational grant from GlaxoSmithKline.Link to full program, including associated downloadable slidesets: https://bit.ly/2QRqYuC 

Matt Kalaycio, MD, of the Cleveland Clinic joins Blood & Cancer host David H. Henry, MD, of Pennsylvania Hospital, Philadelphia, to preview the potentially practice changing research that will be reported at the 2019 annual meeting of the American Society of Hematology. Plus, in Clinical Correlation, Ilana Yurkiewicz, MD, of Stanford (Calif.) University, addresses the isolation that comes from dealing with a serious chronic illness, especially around the holidays. *  *  *  Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 *  *  *  FDA approves atezolizumab combo as first line for advanced NSCLC Atezolizumab is a monoclonal antibody and is already approved for adults with metastatic NSCLC with disease progression. By Laura Nicolaides The Food and Drug administration as approved atezolizumab in combination with paclitaxel and carboplatin chemotherapy for first-line treatment of adults with metastatic, nonsquamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.  *  *  *  ASH abstracts discussed in the podcast: Abstract 1: Post-transplantation cyclophosphamide after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON-96 trial in recipients of matched related and unrelated donors. Abstract 261: Superior survival with post-remission pediatric-inspired chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: Comparison of CALGB 10403 to patients reported to the CIBMTR. Abstract 322: Nonmyeloablative allogeneic transplantation confers an overall survival benefit with similar nonrelapse mortality when compared with autologous stem transplantation for patients with relapsed follicular lymphoma. Abstract 6: Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell therapies, and is active in treatment through multiple lines. Abstract LBA-5: Validation of BCL11A as therapeutic target in sickle cell disease: Results from the adult cohort of a pilot/feasibility gene therapy trial inducing sustained expression of fetal hemoglobin using posttranscriptional gene silencing. Abstract LBA-6: Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: Primary analysis results from the randomized, open-label, phase 3 study Candor. Abstract 1588: A randomized trial of EPOCH-based chemotherapy with vorinostat for highly aggressive HIV-associated lymphomas: Updated results evaluating the impact of diagnosis-to-treatment interval and pre-protocol systemic therapy on outcomes. Abstract 940: Elucidating the role of IL6 in stress erythropoiesis and in the development of anemia under inflammatory conditions. Abstract 57: Patient harm from repetitive blood draws and blood waste in the ICU: A retrospective cohort study. Abstract 59: Impact of iron supplementation on patient outcomes in women undergoing gynecologic procedures: Systematic review and meta-analysis of randomized trials. Abstract 126: Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma: Primary analysis of the full efficacy population in a phase Ib/II trial. Abstract 168: Risk of hemorrhage in patient with polycythemia vera exposed to aspirin in combination with anticoagulants: Results of a prospective, multicenter, observational cohort study (REVEAL). Abstract 326: Safety and effectiveness of apixaban, LMWH, and warfarin among venous thromboembolism patients with active cancer: A retrospective analysis using four U.S. claims databases. Abstract 327: Safety and effectiveness of apixaban, LMWH and warfarin among venous thromboembolism patients with active cancer: A subgroup analysis of VTE risk scale. Abstract 566: Phase II study of oral rigosertib combined with azacytidine as first line therapy in patients with higher-risk myelodysplastic syndromes.   For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd Ilana Yurkiewicz on Twitter: @ilanayurkiewicz

Listen as Dr. Huff discusses the infusion duration for carfilzomib in patients with multiple myeloma.

Dr Stewart talks to ecancertv at ASH 2015 about the ENDEAVOR study that has demonstrated superiority of carfilzomib over bortezomib in patients with relapsed and refractory multiple myeloma. Carfilzomib is a selective proteasome inhibitor approved in many countries for the treatment of relapsed and refractory multiple myeloma. ENDEAVOR was a randomised, phase III study that involved more than 900 patients who were treated with carfilzomib or bortezomib in addition to dexamethasone. The primary results demonstrated a clinically meaningful and statistically significant two-fold improvement in the median progression-free survival was achieved when carfilzomib was used rather than bortezomib (18.7 vs 9.4 months). For patients with multiple myeloma who have one to three prior relapses carfilzomib “is really the proteasome inhibitor of choice,” Dr Stewart suggests.

Dr Siegel talks to ecancer at the 16th International Myeloma Workshop about the ASPIRE trial, looking at carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. He also discusses the ENDEAVOUR trial looking at carfilzomib in combination with low-dose dexamethasone (Kd), versus bortezomib with low-dose dexamethasone (Vd) in patients whose multiple myeloma has relapsed after at least one, but not more than three prior therapeutic regimens. Since presentation at ASH 2015 the data from both trials has matured. Consistent with the primary analyses, the results show that incorporation of carfilzomib into treatment regimens in patients with relapsed or refractory multiple myeloma results in clinically meaningful improvements in progression free survival and a favourable benefit–risk profile.

Dr Boccia speaks with ecancer at the 16th International Myeloma Workshop about the CHAMPION-2 study. The study evaluated different dose levels of carfilzomib in combination with fixed-dose cyclophosphamide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). Carfilzomib is a selective and irreversible second-generation proteasome inhibitor. Carfilzomib (56 mg/m2) twice weekly combined with cyclophosphamide and dexamethasone had manageable toxicity and was effective for treating patients with newly diagnosed MM.

Dr Weisel speaks with ecancer at EHA 2017 about the ENDEAVOR trial, a head to head comparison of bortezomib or carfilzomib with dexamethasone in relapsed/refractory multiple myeloma.

Listen to Dr. Craig Crews of the Crews Laboratory at Yale University describe how a drug begins as an idea and becomes a real myeloma therapy used in the clinic. He shares his story of the discovery and development of the drug carfilzomib (Kyprolis).

Listen to Dr. Craig Crews of the Crews Laboratory at Yale University describe how a drug begins as an idea and becomes a real myeloma therapy used in the clinic. He shares his story of the discovery and development of the drug carfilzomib (Kyprolis).

Prof Philippe Moreau talks to ecancer at the 18th EHA Congress about the results of a phase I/II trial that tested carfilzomib plus melphalanprednisone in elderly patients with newly diagnosed multiple myeloma.

Prof Philippe Moreau talks to ecancer at the 18th EHA Congress about the results of a phase I/II trial that tested carfilzomib plus melphalanprednisone in elderly patients with newly diagnosed multiple myeloma.

This expert panel discussion filmed at the 14th International Myeloma Workshop, 3-7th April, looks at understanding of new data in the diagnosis and prognosis of multiple myeloma. Pomalidomide and carfilzomib have recently been approved in the US for treatment of multiple myeloma (MM). Pomalidomide was approved on the basis of two Phase II trials. A robust response of approximately 30% was seen in both studies in double refractory patients, with durability of response and impressive progression free survival (PFS) and overall survival (OS). In both trials, a predictable and manageable toxicity profile was observed. This drug represents a significant advance in the treatment of MM. Combination studies (with bortezomib and carfilzomib) and subgroup studies are underway. Carfilzomib received accelerated approval last year with low dose dexamethasone as a premedication and now in combination. It has shown clear activity in the context of double refractory relapse disease. Carfilzomib is associated with relatively low rates of neurotoxicity. There are other toxicities, although these are believed to be generally manageable. The oral proteasome inhibitor, MLN9708, has shown favourable tolerability. Its activity in combination also appears to be encouraging. However, it does not seem to be as potent as IV or SC bortezomib. Treatment of high risk smouldering myeloma is a key topic at this year's IMW. Smouldering myeloma is a very heterogeneous group of patients, as it also includes MGUS patients who have a very low rate of progression to MM. At the other end of the spectrum are the high risk patients for progression, sometime referred to as 'early myeloma', most of whom will progress to full-blown MM in 2-3 years. Recent Spanish data has shown that thalidomide and dexamethasone in combination can delay the progression to MM, and improve the OS in this group of patients. Myeloma is not only a heterogeneous disease between individual patients, but also within an individual patient. There is more than one subtype of malignant cell, which has important implications for treatment. At any one time during the disease, a single subtype of clone can be dominant. This has been termed the 'clonal tide' in MM. Because of the changing face of MM over the course of the disease, it is thought that a patient showing initial resistance to a therapy who then relapses can subsequently show sensitivity to this treatment again, as the clonal pattern of their disease changes. It is now possible to track the presence of clones over time and it may be possible to develop a myeloma tool based on next generation sequencing to use in biopsies to monitor the clonal content and intervene early before the clone has become too complex. Several monoclonal antibodies have been investigated in MM in combination with lenalidomide and dexamethasone. Further studies are underway. The assessment of minimal residual disease (MRD) should be assessed both inside the bone marrow and outside the bone marrow. Outside the bone marrow, imaging techniques such as PET scan should become the gold standard. In the bone marrow, there are two imaging techniques available. The first of these is molecular imaging and the second is multiparameter flow cytometry (MFC). The latter is more applicable for use in routine laboratories. A combination of both extramedullary and intramedullary assessments would provide the best tool to help decide on therapy in the future. Currently, studies have shown that a positive MRD can help guide consolidation and maintenance therapy. Bisphosphonates are used routinely in MM patients. A recent study on zoledronic acid has shown that the use of zoledronic acid not only reduced bone disease but improved survival in the patients treated. This is the first time a survival advantage has been seen with supportive care. As a result, guidelines now recom